



## **Session II Genetic Predisposition to WM**

Session Chair: Dr. Kyle (USA)

9:40 AM	Dr. Kyle (USA)	IgM MGUS and Smoldering WM.
9:50 AM	Dr. Morra (ITALY)	Factors predicting evolution in IgM MGUS and IgM-related disorders.
10:00 AM	Dr. Lynch (USA)	Familial predisposition in plasma cell disorders.
10:10 AM	Dr. Ogmundsdottir (ICELAND)	Familial paraproteinemias.
10:20 AM	Dr. Landgren (USA)	Risk Factors for LPL/WM.
10:30 AM	Dr. McMaster (USA)	Environmental Exposures in Familial WM.
10:40 AM	Dr. Hunter (USA)	GWAS Studies in WM.
10:50 AM	Dr. Varettoni (ITALY)	Associated cancers in WM.
11:00 AM	Panel Discussion	All Session II Speakers.

## **Session III Genomic and Epigenomic Alterations in WM**

Session Chair: Dr. Sahota (UK)

11:30 AM	Dr. Braggio (USA)	High resolution aCGH analysis in WM.
11:40 AM	Dr. Poulain (FRANCE)	Genomic/SNP Studies in WM.
11:50 AM	Dr. Nguyen-Khac (FRANCE)	Cytogenetic abnormalities in WM.
12:00 PM	Dr. Sahota (UK)	Probing B-cell receptor in WM.
12:10 PM	Dr. Dunn-Walters (UK)	Immunoglobulin repertoire analysis of B-Cell populations: Clues to the origins of WM.
12:20 PM	Dr. Zhou (USA)	Ets-family dysregulation in WM.
12:30 PM	Panel Discussion	All Session III Speakers.

**1:00-2:00 PM**

**Session Break and Lunch.**  
***"Venetian Foyer"***

**1:30-1:45 PM**

**Special Lunch Lecturer:**  
**Dr. Steve Bogen (USA)**  
***"Identification of antigenic determinants in WM"***

## **Session IV Immunological Dysregulation in WM**

Session Chair: Dr. Joshua (Australia)

2:00 PM	Dr. Joshua (AUSTRALIA)	Clonal Expansion of CTLs in WM.
2:10 PM	Dr. Gorochov (FRANCE)	Impaired regulatory T-cell function in WM.
2:20 PM	Dr. Munshi (USA)	Role of TH17 pathway in WM.
2:30 PM	Dr. Jiang (USA)	Monocytic dysregulation in WM.
2:40 PM	Dr. Grass (GERMANY)	Hyperphosphorylated Paratag-7 is a frequent target in WM.
2:50 PM	Dr. Rawstron (UK)	Humoral immune suppression in indolent B-cell malignancies.
3:00 PM	Panel Discussion	All Session IV Speakers

*Refreshments will be available during Panel Discussion IV*

**Session V Molecular Pathways in Growth and Survival of WM**

Session Chair: Dr. Anderson (USA)

3:30 PM	Dr. Ansell (USA)	Jak Stat Pathway in WM.
3:40 PM	Dr. Terpos (GREECE)	Angiogenic Support in WM.
3:50 PM	Dr. Roccaro (ITALY)	MicroRNAs in WM pathogenesis.
4:00 PM	Dr. Cao (USA)	Aberrant MicroRNA regulation of IRS-PI3K pathway in WM.

**4:10-4:30 PM**

**Special Lecturer:**

**Dr. Ken Anderson (USA)**

**Role of Plasmacytoid Dendritic Cells in plasma cell growth and survival.**

4:30 PM	Panel Discussion	All Session IV Speakers
5:00 PM	Dr. Treon (USA)	Day Summary and Adjournment





**6<sup>th</sup> International Workshop on  
Waldenström's Macroglobulinemia  
October 6-10, 2010  
Venice, Italy**

**Friday, October 8, 2010**

**Molino Stucky Hilton**

**Workshop Program**

7:00-8:00 AM

Breakfast

Registration

Molino Restaurant

Venetian Foyer (7:00-17:30)

**7:00 AM Consensus Discussions on Treatment Options and Response  
Criteria in WM-Part I**

Drs. Owen (UK) and Treon (USA)

Presentation of Current Consensus Treatment Guidelines and Proposed Updates  
Dr. Treon (USA)

*Refreshments will be available during Consensus Discussions*

**Session VI Prognostic and Predictive Factors in WM**

Session Chair: Dr. Morel (FRANCE)

8:00 AM	Dr. Morel (FRANCE)	Can WM ISS be used to make treatment decisions?
8:10 AM	Dr. Thomas (USA)	ISSMM and ISSWM as prognosticators in WM.
8:20 AM	Dr. Kastiris (GREECE)	Prognostication of the high risk WM patient.
8:30 AM	Dr. Kristinsson (SWEDEN)	Survival in Patients with LPL/WM.
8:40 AM	Dr. Treon (USA)	Fcy polymorphisms and depth of response as predictors of outcome to rituximab based therapy in WM.
8:50 AM	Panel Discussion	All Session VI Speakers.

**Session VII Novel Therapeutic Approaches to WM-Preclinical**

Session Chair: Dr. Mitsiades (USA)

9:10 AM	Dr. Mitsiades (USA)	Novel Proteasome Inhibitors.
9:20 AM	Dr. Yang (USA)	Preclinical studies of GA101 antibody in WM.
9:30 AM	L. Xu (USA)	Hypomethylation agents in WM.
9:40 AM	Panel Discussion	All Session VII Speakers.

*Refreshments will be available during Panel Discussion VIII*

**Session VIII Treatment of WM- Part I**

Session Chair: Dr. Rummel (Germany)

10:00 AM	Dr. Owen (UK)	Phase III Study of Chlorambucil vs. Fludarabine as initial therapy in WM.
10:10 AM	Dr. Tedeschi (ITALY)	Multicenter Study of FCR in untreated & previously treated WM.
10:20 AM	Dr. Rummel (GERMANY)	Primary Therapy of WM with Bendamustine and Rituximab.
10:30 AM	Dr. Hoster (GERMANY)	Frontline Treatment options in WM: German Experience.
10:40 AM	Dr. Treon (USA)	Update on Frontline Treatment Studies in WM.
11:00 AM	Panel Discussion	All Session VIII Speakers

**Session IX Treatment of WM-Part II**

Session Chair: Dr. Ghobrial (USA)

11:20 AM	Dr. Laszlo (ITALY)	Phase II study of Rituximab and subcutaneous 2CDA in WM.
11:30 AM	Dr. Rossi (FRANCE)	Phase I Study of Atacicept in relapsed/refractory MM and WM.
11:40 AM	L. Ioakimidis (USA)	Maintenance rituximab in WM.
11:50 AM	Dr. Ghobrial (USA)	Update on Salvage Treatment Studies in WM.
12:10 AM	Panel Discussion	All Session XI Speakers

**12:30-1:30 PM**

**Session Break and Lunch.**  
*"Venetian Foyer"*

**1:00-1:20 PM**

**Special Lunch Lecturer:**  
**Dr. Stephanie Gregory (USA)**  
**"Novel Treatment Options for B-cell malignancies".**

**Session X      Response Assessment in WM**

Session Chair: Dr. Owen (UK)

1:30 PM	Dr. Owen (UK)	Challenges with response assessment in WM.
1:40 PM	Dr. Garcia-Sanz (SPAIN)	Flow cytometric evaluation of WM response.
1:50 PM	Dr. Leleu (FRANCE)	sFLC in response assessment in WM.
2:00 PM	Panel Discussion	All Session VII Speakers.

**Session XI      Treatment Challenges in WM**

Session Chair: Dr. Munshi (USA)

2:20 PM	<b>Challenges in the Management of the WM Patient</b> Dr. Munshi (USA)	
2:30 PM	<b>Debate: Is there a role for nucleoside analogue therapy in WM?</b> YES- Dr. Morra (ITALY)                      NO- Dr. Leleu (FRANCE)	
3:00 PM	<b>Debate: Should Benda-Rituximab be considered the standard as frontline therapy in WM?</b> YES- Dr. Rummel (GERMANY)              NO- Dr. Leblond (FRANCE)	
3:30 PM	<b>Debate: Should maintenance rituximab be used for rituximab responders in WM?</b> YES- Dr. Advani (USA)                      NO- Dr. Kimby (SWEDEN)	
4:00 PM	<b>Debate: Should ASCT be a frontline option for WM?</b> YES- Dr. Kyriakou (UK)                      NO- Dr. Fermand (FRANCE)	
4:30 PM	<b>Debate: Should allogeneic transplant represent a standard of care option in WM?</b> YES-Dr. Maloney (USA)                      NO- Dr. Barlogie (USA)	

*Refreshments will be available during Debates*

5:00 PM	Dr. Morra (ITALY)	Day Summary and Adjournment
---------	-------------------	-----------------------------





**6<sup>th</sup> International Workshop on  
Waldenström's Macroglobulinemia  
October 6-10, 2010  
Venice, Italy**

**Saturday, October 9, 2010**

**Molino Stucky Hilton**

7:00-8:00 AM

Breakfast

Registration

Molino Restaurant

Venetian Foyer (7:00-17:30)

**7:00 AM**

**Consensus Discussions on Treatment Options and Response  
Criteria in WM-Part II**

Drs. Owen (UK) and Treon (USA)

Presentation of Current Consensus Response Criteria and Proposed Updates  
Dr. Owen (UK)

**Session XII Young Investigator Presentations**

**Section I:**

Session Chair: Dr. Ansell (USA)

8:00 AM

Dr. Novak (USA)

Development of WM cell lines.

8:15 AM

M. Lewicki (CANADA)

Assessment of cytokines and chemokines  
in patients with WM.

8:30 AM

Dr. Koulieris (GREECE)

Quantification of IgM kappa and IgM  
lambda in WM.

8:45 AM

S. Guidez (FRANCE)

SM-IgC as response criteria in WM.

9:00 AM

Dr. Greco (ITALY)

Factors predicting malignant evolution of  
IgM-MGUS and IgM related disorders.

**Section II:**

Session Chair: Dr. Ocio (SPAIN)

9:15 AM

Dr. Trojani (ITALY)

Gene expression of malignant and micro-  
environment cells from WM patients.

9:30 AM

Dr. Fulcinitti (USA)

Sp1 trans-activation in WM.

9:45 AM

Dr. Liu (USA)

Metalloprotease inhibitors and CD27 in WM.

10:00 AM

A. Sacco (USA)

NVP-BEZ235 exerts anti-tumor activity in WM.

Section III:

Session Chair: Dr. Kimby (SWEDEN)

10:15 AM	Dr. Maltezas (GREECE)	Clinical impact of sFLCs or FLCR on WM.
10:30 AM	L. Compain (FRANCE)	Rituximab, Fludarabine and Cyclophosphamide in WM.
10:45 AM	Dr. Chitta (USA)	Induced resistance to Bortezomib and its association with BCL-2 up-regulation.
11:00 PM	Dr. Azab (USA)	Role of hypoxia in the dissemination of WM.
11:15 PM	Dr. Ricci (ITALY)	Impact of advanced age in WM at diagnosis.
11:30 AM	Dr. Hospital (FRANCE)	Anti-MAG neuropathy.

*Refreshments will be available during YIA presentations*

**11:45-1:00 PM**

**Session Break and Lunch.  
"Venetian Foyer"**

**12:00-12:15 PM**

**Special Lunch Lecturer:  
Dr. Umberto Vitolo (ITALY)  
"Update in Indolent NHL: Paradigm for WM".**

**12:15-12:30 PM**

**Special Guest Lecturer:  
Dr. Mario Boccadoro (ITALY)  
"Update in Multiple Myeloma Therapy: Paradigm for WM".**

**Session XIII Focus on WM related Peripheral Neuropathy**

Session Chair: Dr. Hochberg (USA)

1:00 PM	Dr. Nobile-Orazio (ITALY)	Antigenic determinants in IgM related PN.
1:15 PM	Dr. Levine (USA)	Treatment of painful neuropathies in WM.
1:30 PM	Dr. Steck (SWITZERLAND)	Rituximab for anti-MAG Neuropathy.
1:45 PM	Dr. Karlin (FRANCE)	Combination therapy of WM related PN.
2:00 PM	NP. Sheehy (USA)	Natural history and treatment outcome of WM related PN.

**Session XIV Focus on WM related Morbidities in WM-Part I**

Session Chair: Dr. Stone (USA)

2:15 PM	Dr. Merlini (ITALY)	Diagnosis and Therapy of Amyloidosis.
2:30 PM	Dr. Gertz (USA)	Management of IgM-Related Amyloidosis.
2:45 PM	Dr. Fermand (FRANCE)	Renal Manifestations of WM.
3:00 PM	Dr. Asli (FRANCE)	Physiopathology of Schnitzler's Syndrome.



**Session XV Focus on WM related Morbidities in WM-Part II**

Session Chair: Dr. Fermand (France)

3:15 PM	Dr. Stone (USA)	Pathogenesis and Morbidity of Autoantibody Syndromes in WM.
3:30 PM	Dr. Berentsen (NORWAY)	Management of Cold Agglutinin Disease.
3:45 PM	Dr. Dammacco (ITALY)	HCV-positive Macroglobulinemia.
4:00 PM	Dr. Owen (UK)	Histologic Transformation of WM.
4:15 PM	Dr. Hochberg (USA)	Bing Neel Syndrome.
4:30 PM	Dr. Merlini (ITALY)	Day Summary and Adjournment





**6<sup>th</sup> International Workshop on  
Waldenström's Macroglobulinemia  
October 6-10, 2010  
Venice, Italy**

**Sunday, October 10, 2010 Molino Stucky Hilton  
IWMF European WM Patient and Physician Forum**

7:00-8:00 AM		
Continental Breakfast		Venetian Foyer (7:00-8:00)
Registration		Venetian Foyer (7:00-17:30)
8:00 AM	Judith May, IWMF Dr. Enrica Morra (ITALY) Dr. Giampaolo Merlini (ITALY)	Welcome Address
8:30 AM	Dr. Kyle (USA)	Introduction to WM.
9:00 AM	Dr. Kimby (SWEDEN)	Complications in WM.
9:30 AM	Dr. Morra (ITALY)	Current WM Treatments in WM.
<b>10:00-10:15 AM</b>		<b>Session Break and Refreshments.</b>
10:15 AM	Dr. Kyriakou (UK)	Role of Autologous and Allogeneic Transplants in WM.
10:45 AM	Dr. Treon (USA)	Novel Treatments in WM.
11:15 AM	Physician Panel	Ask the Doctor Session
<b>12:00-1:30 PM</b>		<b>Session Break and Lunch. "Venetian Foyer"</b>
1:30-2:00 PM	Dr. Merlini (ITALY)	<u>Special Guest Lecturer:</u> "Presentation on Dr. Jan Waldenström".
2:00 - 3:00 PM		Patient Panel Session.
3:00 - 3:45 PM		Breakout Groups I
<b>3:45 - 4:00 PM</b>		<b>Session Break and Refreshments</b>
4:00 - 4:45 PM		Breakout Groups II
4:45 - 5:00 PM		Day Summary and Adjournment